Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta
Emilio
E
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000706:statistics & numerical data; D003606:Dacarbazine / Q000627:therapeutic use; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary / Q000628:therapy; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009367:Neoplasm Staging; D018579:Patient Selection; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins; D012306:Risk; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis; D017211:Treatment Failure
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003606:Dacarbazine